Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to Meridian Bioscience Reports First Quarter 2017 Operating Results, Reduces Regular Cash Dividend, and Revises Fiscal 2017 Guidance Downward

Meridian Bioscience (VIVO) Misses Q1 EPS by 5c; Lowers Outlook, Cuts Dividend

January 25, 2017 7:38 AM EST

Meridian Bioscience (NASDAQ: VIVO) reported Q1 EPS of $0.15, $0.05 worse than the analyst estimate of $0.20. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $51.1 million.

GUIDANCE:

Meridian Bioscience sees FY2017 EPS of $0.64-$0.69, versus the consensus of $0.82.... More